

# Athanasios Anastasilakis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7000811/publications.pdf>

Version: 2024-02-01

146  
papers

4,226  
citations

147726

31  
h-index

138417

58  
g-index

149  
all docs

149  
docs citations

149  
times ranked

4980  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adult Langerhans Cell Histiocytosis and the Skeleton. <i>Journal of Clinical Medicine</i> , 2022, 11, 909.	1.0	3
2	The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis. <i>Bone</i> , 2022, 158, 116354.	1.4	2
3	Response to Letter to the Editor From Taguchi: "Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS" <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	1.8	0
4	Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1441-1460.	1.8	35
5	Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough. <i>Journal of Clinical Densitometry</i> , 2021, 24, 338-340.	0.5	9
6	Circulating and Tissue Expression Profile of <sc>MicroRNAs</sc> in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas. <i>JBMR Plus</i> , 2021, 5, e10431.	1.3	1
7	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 264-281.	1.8	132
8	Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 152.	1.0	89
9	Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. <i>Calcified Tissue International</i> , 2021, 108, 587-594.	1.5	8
10	Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation. <i>Journal of Clinical Densitometry</i> , 2021, 24, 591-596.	0.5	7
11	The Impact of Antiosteoporotic Drugs on Glucose Metabolism and Fracture Risk in Diabetes: Good or Bad News?. <i>Journal of Clinical Medicine</i> , 2021, 10, 996.	1.0	12
12	Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion. <i>Endocrine</i> , 2021, 73, 223-225.	1.1	0
13	Parathyroid Disease in Pregnancy and Lactation: A Narrative Review of the Literature. <i>Biomedicines</i> , 2021, 9, 475.	1.4	4
14	Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. <i>Maturitas</i> , 2021, 147, 19-25.	1.0	19
15	Denosumab for the treatment of primary pediatric osteoporosis. <i>Osteoporosis International</i> , 2021, 32, 2377-2381.	1.3	6
16	Î™risin levels in postmenopausal women with an incident hip fracture. <i>Endocrine</i> , 2021, 73, 719-722.	1.1	2
17	The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4155-e4162.	1.8	31
18	Irisin in nonalcoholic fatty liver disease: need for an updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154818.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Teriparatide Treatment in Patients with Pregnancy- and Lactation-Associated Osteoporosis. <i>Calcified Tissue International</i> , 2021, 109, 554-562.	1.5	11
20	Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients. <i>Bone Reports</i> , 2021, 15, 101128.	0.2	7
21	Questions and facts regarding denosumab discontinuation among postmenopausal women. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 499-501.	1.0	2
22	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e390-e400.	1.8	29
23	Fracture risk among treatment-naïve postmenopausal women with osteopenia in Greece: results from the "ACROSS" study. <i>Archives of Osteoporosis</i> , 2020, 15, 163.	1.0	1
24	Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. <i>Bone Reports</i> , 2020, 12, 100267.	0.2	22
25	Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2885-e2894.	1.8	11
26	The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. <i>Bone</i> , 2020, 138, 115478.	1.4	26
27	Combination and sequential treatment in women with postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 477-490.	0.9	33
28	Gender Predilection in Sporadic Parathyroid Adenomas. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2964.	1.8	5
29	Management of parathyroid disorders: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society. <i>Hormones</i> , 2020, 19, 581-591.	0.9	4
30	Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation. <i>Endocrine</i> , 2020, 69, 516-518.	1.1	7
31	SUN-LB65 Circulating Micromas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
32	Hypoparathyroidism: is it that easy to treat?. <i>Hormones</i> , 2019, 18, 55-63.	0.9	2
33	Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2220-2228.	3.1	103
34	Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. <i>Bone</i> , 2019, 127, 401-418.	1.4	33
35	Off-label uses of denosumab in metabolic bone diseases. <i>Bone</i> , 2019, 129, 115048.	1.4	37
36	Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. <i>Metabolism: Clinical and Experimental</i> , 2019, 93, 100-102.	1.5	11

#	ARTICLE	IF	CITATIONS
37	Bazedoxifene for the treatment of osteoporosis. Expert Opinion on Pharmacotherapy, 2019, 20, 1201-1210.	0.9	42
38	The 2018 Guidelines for the diagnosis and treatment of osteoporosis in Greece. Archives of Osteoporosis, 2019, 14, 39.	1.0	28
39	Beyond glycemc control: New guidance on cardio-renal protection. Metabolism: Clinical and Experimental, 2019, 99, 113-115.	1.5	5
40	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism: Clinical and Experimental, 2019, 101, 154005.	1.5	83
41	Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls. Hormone and Metabolic Research, 2019, 51, 112-119.	0.7	7
42	Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. Hormones, 2019, 18, 65-70.	0.9	12
43	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone, 2019, 120, 44-49.	1.4	19
44	Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. Journal of Musculoskeletal Neuronal Interactions, 2019, 19, 253-257.	0.1	0
45	Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. Calcified Tissue International, 2018, 103, 107-108.	1.5	7
46	THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. European Journal of Endocrinology, 2018, 179, R31-R45.	1.9	94
47	Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1206-1213.	1.8	48
48	Bone disease in primary hyperparathyroidism. Metabolism: Clinical and Experimental, 2018, 80, 57-65.	1.5	40
49	Irisin in metabolic diseases. Endocrine, 2018, 59, 260-274.	1.1	178
50	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones, 2018, 17, 573-579.	0.9	6
51	Bone metabolism in Langerhans cell histiocytosis. Endocrine Connections, 2018, 7, R246-R253.	0.8	11
52	Regulation of the activins-follistatins-inhibins axis by energy status: Impact on reproductive function. Metabolism: Clinical and Experimental, 2018, 85, 240-249.	1.5	32
53	Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis. Metabolism: Clinical and Experimental, 2017, 69, 107-111.	1.5	14
54	Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. Journal of Bone and Mineral Research, 2017, 32, 1291-1296.	3.1	270

#	ARTICLE	IF	CITATIONS
55	Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. <i>Metabolism: Clinical and Experimental</i> , 2017, 73, 1-8.	1.5	53
56	Bisphosphonates or denosumab discontinuation and risk of fractures. <i>Maturitas</i> , 2017, 102, 75.	1.0	4
57	Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 198-201.	1.5	2
58	Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. <i>European Journal of Endocrinology</i> , 2017, 176, 677-683.	1.9	70
59	Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1137-1144.	1.9	13
60	Physiological parameters regulating circulating levels of the IGFBP-4/Stanniocalcin-2/PAPP-A axis. <i>Metabolism: Clinical and Experimental</i> , 2017, 75, 16-24.	1.5	15
61	Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. <i>Archives of Osteoporosis</i> , 2017, 12, 58.	1.0	44
62	Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures. <i>European Journal of Endocrinology</i> , 2017, 176, 169-176.	1.9	86
63	Circulating periostin in patients with nonalcoholic fatty liver disease. <i>Endocrine</i> , 2017, 56, 438-441.	1.1	6
64	Periostin and sclerostin levels in juvenile Paget's disease. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2017, 14, 269.	1.0	2
65	Development and validation of an osteoporosis treatment questionnaire (OSTREQ) evaluating physicians' criteria in the choice of treatment. <i>Hormones</i> , 2016, 15, 413-422.	0.9	0
66	Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1459-1465.	1.5	19
67	Activin A and follistatin in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1550-1558.	1.5	27
68	Periostin on the road to nonalcoholic fatty liver disease. <i>Endocrine</i> , 2016, 51, 4-6.	1.1	4
69	Serum leptin, adiponectin and ghrelin concentrations in post-menopausal women: Is there an association with bone mineral density?. <i>Maturitas</i> , 2016, 88, 32-36.	1.0	29
70	Multiple clinical vertebral fractures following denosumab discontinuation. <i>Osteoporosis International</i> , 2016, 27, 1929-1930.	1.3	75
71	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. <i>Journal of Bone and Mineral Metabolism</i> , 2016, 34, 447-456.	1.3	24
72	Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, L89-L90.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Annual Seminar of Hellenic Osteoporosis Foundation The role of mechanical factors on the musculoskeletal system. Journal of Frailty, Sarcopenia and Falls, 2016, 01, 58-72.	0.4	0
74	The effect of smoking on clinical and radiographic variables, and acute phase reactants in patients with ankylosing spondylitis. Rheumatology International, 2015, 35, 2109-2114.	1.5	17
75	Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease. Endocrine, 2015, 49, 560-562.	1.1	16
76	P1017 : Circulating sclerostin and DICKKOPF-1 in patients with Nonalcoholic Fatty Liver Disease. Journal of Hepatology, 2015, 62, S729.	1.8	0
77	Novel therapies for osteoporosis. Metabolism: Clinical and Experimental, 2015, 64, 1199-1214.	1.5	62
78	Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. Metabolism: Clinical and Experimental, 2015, 64, 1291-1297.	1.5	24
79	Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Expert Opinion on Investigational Drugs, 2015, 24, 145-157.	1.9	17
80	Cost-effective osteoporosis treatment thresholds in Greece. Osteoporosis International, 2015, 26, 1949-1957.	1.3	28
81	Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporosis International, 2015, 26, 2521-2527.	1.3	49
82	Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. Expert Opinion on Therapeutic Targets, 2015, 19, 299-306.	1.5	16
83	Rationale for the Application of RANKL Inhibition in the Treatment of Langerhans Cell Histiocytosis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E282-E286.	1.8	8
84	Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation. Rheumatology, 2015, 54, 908-914.	0.9	30
85	Circulating Periostin Levels do not Differ Between Postmenopausal Women with Normal and Low Bone Mass and are not Affected by Zoledronic Acid Treatment. Hormone and Metabolic Research, 2014, 46, 145-149.	0.7	25
86	The Effect of Leptin Replacement on Parathyroid Hormone, RANKL-Osteoprotegerin Axis, and Wnt Inhibitors in Young Women With Hypothalamic Amenorrhea. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2252-E2258.	1.8	25
87	Irisin in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2014, 63, 207-217.	1.5	179
88	Denosumab Treatment for Juvenile Paget's Disease: Results From Two Adult Patients With Osteoprotegerin Deficiency (αBalkan Mutation in the <i>TNFRSF11B</i> Gene). Journal of Clinical Endocrinology and Metabolism, 2014, 99, 703-707.	1.8	38
89	Circulating Irisin in Healthy, Young Individuals: Day-Night Rhythm, Effects of Food Intake and Exercise, and Associations With Gender, Physical Activity, Diet, and Body Composition. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3247-3255.	1.8	133
90	Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporosis International, 2014, 25, 1633-1642.	1.3	111

#	ARTICLE	IF	CITATIONS
91	THU0080â€¦.Association of Serum Periostin Levels with Disease Activity and Radiographic Damage, as Well as Serum Bone Formation Markers, in Patients with Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 204.2-204.	0.5	0
92	Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. <i>Osteoporosis International</i> , 2013, 24, 2127-2132.	1.3	12
93	Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. <i>Rheumatology International</i> , 2013, 33, 2917-2920.	1.5	14
94	Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3206-3212.	1.8	46
95	Coexistence of Gravesâ€™ disease, papillary thyroid carcinoma and unilateral benign struma ovarii: Case report and review of the literature. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1350-1356.	1.5	20
96	Disease-modifying anti-rheumatic drugs for refractory severe knee synovitis in patients with peripheral spondyloarthritis: efficacy and predictors of response. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 369-372.	0.6	1
97	Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. <i>Clinical Endocrinology</i> , 2013, 79, 499-503.	1.2	52
98	Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum. <i>Cytokine</i> , 2013, 61, 127-132.	1.4	20
99	Serum sclerostin levels following treatment with parathyroid hormone. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 280-280.	1.8	1
100	Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in Patients with Peripheral Spondyloarthritis. <i>ISRN Rheumatology</i> , 2013, 2013, 1-4.	1.9	1
101	Central skeletal sarcoidosis: a case report with sustained remission only on methotrexate, and a literature review on the imaging approach, treatment, and assessment of disease activity. <i>Modern Rheumatology</i> , 2013, 23, 175-181.	0.9	11
102	Is Serum IL-17A a Useful Systemic Biomarker in Patients With Langerhans Cell Histiocytosis?. <i>Molecular Therapy</i> , 2012, 20, 6-7.	3.7	11
103	Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E618-E621.	1.8	10
104	Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. <i>Bone</i> , 2012, 50, 1130-1134.	1.4	30
105	The role of cytokines and adipocytokines in zoledronateâ€¦induced acute phase reaction in postmenopausal women with low bone mass. <i>Clinical Endocrinology</i> , 2012, 77, 816-822.	1.2	6
106	Acute transient thyroid swelling following needle biopsy: An update. <i>Hormones</i> , 2012, 11, 147-150.	0.9	14
107	Papillary thyroid microcarcinoma presenting as lymph node metastasis â€œ a diagnostic challenge: case report and systematic review of literature. <i>Hormones</i> , 2012, 11, 419-427.	0.9	7
108	Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2012, 58, 819-822.	0.8	15

#	ARTICLE	IF	CITATIONS
109	Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 295.	0.9	69
110	Oxidized low-density lipoprotein and adiponectin levels in pregnancy. <i>Gynecological Endocrinology</i> , 2011, 27, 1070-1073.	0.7	17
111	Denosumab and bisphosphonates: Rivals or potential "partners"? A "hybrid" molecule hypothesis. <i>Medical Hypotheses</i> , 2011, 77, 109-111.	0.8	4
112	Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. <i>Hormones</i> , 2011, 10, 174-195.	0.9	23
113	Apelin levels in normal pregnancy. <i>Clinical Endocrinology</i> , 2011, 75, 367-371.	1.2	34
114	Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 178-186.	1.6	43
115	No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response. <i>Calcified Tissue International</i> , 2011, 88, 402-408.	1.5	18
116	A case report of subacute thyroiditis during pregnancy: difficulties in differential diagnosis and changes in cytokine levels. <i>Gynecological Endocrinology</i> , 2011, 27, 384-390.	0.7	9
117	Role of wingless tail signaling pathway in osteoporosis. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011, 18, 383-388.	1.2	18
118	Authors' Response to Dr. Lutz Schomburg. <i>Thyroid</i> , 2011, 21, 564-565.	2.4	0
119	Serum vaspin levels in normal pregnancy in comparison with non-pregnant women. <i>European Journal of Endocrinology</i> , 2011, 164, 579-583.	1.9	21
120	The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. <i>Clinical Endocrinology</i> , 2010, 72, 752-757.	1.2	52
121	A Systematic Review of Cases Reporting Needle Tract Seeding Following Thyroid Fine Needle Biopsy. <i>World Journal of Surgery</i> , 2010, 34, 844-851.	0.8	46
122	Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 108-110.	1.3	4
123	Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 314-319.	1.3	8
124	Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 706-712.	1.3	26
125	Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010, 54, 578-582.	1.3	4
126	Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 673-679.	1.2	3

#	ARTICLE	IF	CITATIONS
127	Dual-Energy X-Ray Absorptiometry and Quantitative Ultrasound in Patients With Paget's Disease of Bone Before and After Treatment With Zoledronic Acid: Association With Serum Bone Markers and Dickkopf-1. <i>Journal of Clinical Densitometry</i> , 2010, 13, 190-196.	0.5	3
128	Selenium Supplementation in the Treatment of Hashimoto's Thyroiditis: A Systematic Review and a Meta-analysis. <i>Thyroid</i> , 2010, 20, 1163-1173.	2.4	150
129	Alterations in Serum Thyroid-Related Constituents After Thyroid Fine-Needle Biopsy: A Systematic Review. <i>Thyroid</i> , 2010, 20, 265-271.	2.4	21
130	Thiazolidinedione use and the risk of fractures. <i>Cmaj</i> , 2009, 180, 841-842.	0.9	9
131	Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. <i>Supportive Care in Cancer</i> , 2009, 17, 1329-1330.	1.0	13
132	Clinical complications following thyroid fine-needle biopsy: a systematic review. <i>Clinical Endocrinology</i> , 2009, 71, 157-165.	1.2	149
133	No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. <i>Clinical Endocrinology</i> , 2009, 70, 522-526.	1.2	8
134	The effect of zoledronic acid on serum Dickkopf-1, osteoprotegerin and rankl in patients with paget's disease of bone. <i>Bone</i> , 2009, 44, S289.	1.4	1
135	Paget's disease of bone: emphasis on treatment with zoledronic acid. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 423-434.	1.2	10
136	RANKL inhibition for the management of patients with benign metabolic bone disorders. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1085-1102.	1.9	30
137	Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1591-1600.	3.1	241
138	Acute changes in serum osteoprotegerin and receptor activator for nuclear factor- $\kappa$ B ligand levels in women with established osteoporosis treated with teriparatide. <i>European Journal of Endocrinology</i> , 2008, 158, 411-415.	1.9	29
139	Endogenous Intact PTH is Suppressed during Teriparatide (rhPTH 1-34) Administration in Postmenopausal Women with Established Osteoporosis. <i>Endocrine Journal</i> , 2008, 55, 613-616.	0.7	15
140	Subendothelial Carotid Hematoma After Fine-Needle Aspiration Biopsy of a Solitary Thyroid Nodule. <i>Journal of Ultrasound in Medicine</i> , 2008, 27, 1517-1520.	0.8	16
141	Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. <i>Hormones</i> , 2007, 6, 233-41.	0.9	7
142	Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
143	Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. <i>Bone Abstracts</i> , 0, , .	0.0	0
144	Circulating microRNAs in postmenopausal women with osteoporosis and vertebral fractures. <i>Bone Abstracts</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
145	Serum leptin, adiponectin and ghrelin concentrations in post-menopausal women: is there an association with bone mineral density?. Endocrine Abstracts, 0, , .	0.0	0
146	Serum and tissue expression profile of microRNAs that regulate genes related to the pathogenesis of sporadic parathyroid adenomas. Endocrine Abstracts, 0, , .	0.0	0